13F Holdings
中文EN

ACIU AC Immune SA IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1651625 · Reporting currency CHF · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-86.9%
TTM net income YoY-38.4%
TTM EPS YoY-37.3%
Revenue 3-yr CAGR-3.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,940.1%
Net margin-1,971.6%
FCF margin-1,963.7%
EBITDA margin—

Returns

ROE-89.7%
ROA-36.6%
ROIC (approx.)-116.4%
Asset turnover0.02x

Leverage & solvency

Liabilities / assets70.9%
Debt / equity0.00x
Current ratio1.02x
Interest coverage-362.92x

Cash quality & payout

Operating cash flow / net income0.98x
Accruals ratio-0.6%
Payout ratio—
Capex / revenue25.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: CHF FY2025*2025-12-31FY2024*2024-12-31FY2023*2023-12-31FY2022*2022-12-31FY2021*2021-12-31
Income statement
Revenue3.57M27.31M14.80M3.94M0
R&D expense56.44M62.57M54.61M60.34M62.28M
SG&A expense16.09M17.26M15.30M15.79M17.91M
Operating income-69.32M-52.38M-53.62M-70.85M-79.01M
Interest expense191,000133,000176,000355,000581,000
Pretax income-70.45M-50.91M-54.22M-70.74M-72.99M
Income tax03,00010,00013,0003,000
Net income-70.45M-50.92M-54.23M-70.75M-73.00M
EPS (basic)-0.70-0.51-0.64-0.85-0.97
EPS (diluted)-0.70-0.51-0.64-0.85-0.97
Weighted avg. shares (diluted)100.75M99.69M84.69M83.55M74.95M
Balance sheet
Cash & equivalents26.80M36.27M78.49M31.59M82.22M
Short-term investments64.62M129.21M24.55M91.00M116.00M
Receivables—014.80M——
Current assets96.72M171.99M125.15M128.09M202.63M
PP&E, netmay include right-of-use assets (IFRS)1.99M2.65M3.38M4.26M5.12M
Intangibles50.42M50.42M50.42M50.42M50.42M
Total assets154.25M230.91M182.81M185.94M261.44M
Current liabilities94.69M100.84M13.58M11.48M20.03M
Total liabilities109.37M118.64M22.17M16.95M29.46M
Shareholders' equity44.88M112.27M160.64M168.99M231.98M
Cash flow statement
Operating cash flow-69.26M65.84M-60.41M-73.57M-65.69M
Capital expenditure900,000576,000801,0001.24M2.63M
Free cash flow-70.16M65.27M-61.21M-74.81M-68.32M
Investing cash flow63.54M-105.29M65.64M23.76M-53.66M
Financing cash flow-1.02M-1.12M43.25M-1.35M40.75M
Stock-based compensation4.40M5.47M4.37M3.33M4.13M
Share buybacks———00

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company does not report gross profit in XBRL.

· Amounts are in the company's reporting currency, CHF, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.